FDA approves new nonopioid painkiller for acute pain

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x

FDA approves new nonopioid painkiller for acute pain

A comprehensive look at local, statewide and national news events is provided by the NewsChannel 13 Team, along with updates on sports and the weather forecast.

On Thursday, in a major step forward in pain management, the U.S. Food and Drug Administration has approved a new nonopioid painkiller that could change the way doctors treat acute pain. The drug, developed by Vertex Pharmaceuticals, is called Journavx, or suzetrigine, and is designed to provide relief without the risk of addiction.

The FDA’s approval of Journavx marks what experts are calling a significant public health milestone. The drug is aimed at adults experiencing moderate to severe short-term pain and could offer an alternative to opioids, which have long been a leading cause of addiction across the U.S., with Massachusetts and Vermont among the states with the most deaths due to overdoses.

Suzetrigine works differently from opioids—it blocks pain signals at their source before they even reach the brain. Unlike traditional opioid medications, which activate the brain’s reward system and can lead to addiction, this new drug does not stimulate opioid receptors and has shown no addictive potential.

Experts say this could be a game changer for post-surgical patients and those who cannot take traditional pain relievers like ibuprofen or acetaminophen. However, some researchers caution that more studies are needed to understand the drug’s long-term effects fully.

Still, medical professionals are optimistic. Dr. Richard Rosenquist of the Cleveland Clinic says that while opioids remain effective in pain treatment, any alternative that reduces dependency risks is a welcome addition to the medical field.

The approval of Journavx is seen as a hopeful step in the fight against opioid dependence. As more research emerges, doctors and patients alike will be watching closely to see how this new treatment performs in real-world settings.